Fig. 5

Analysis of patient-derived gastric tumor growth in experimental animals treated with hOA-DN30. a Analysis of tumor growth in NOD-SCID mice subcutaneously implanted with GTR-561 gastric PDX treated with 30 mg/kg of hOA-DN30 2xweek. b Analysis of tumor growth in NOD-SCID mice subcutaneously implanted with SG-16 gastric PDX treated with hOA-DN30 (30 mg/kg, 2xweek). Red boxes: period of hOA-DN30 administration; red arrows: antibody deliveries; bars represent SD. Statistical significance evaluated by Two-way Anova analysis is reported; ****, p<0.0001